Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning. Export

@article{citeulike:2180193, abstract = {BACKGROUND: Currently, there are no satisfactory biomarkers available to screen for diffuse large B cell lymphoma (DLBCL) or to identify patients who do not benefit from standard anti-cancer therapies. In this study, we used serum proteomic mass spectra to identify potential serum biomarkers and biomarker patterns for detecting DLBCL and patient responses to therapy. METHODS: The proteomic spectra of crude sera from 132 patients with DLBCL and 75 controls were performed by SELDI-TOF-MS and analyzed by Biomarker Patterns Software. RESULTS: Nine peaks were considered as potential DLBCL discriminatory biomarkers. Four peaks were considered as biomarkers for predicting the patient response to standard therapy. The proteomic patterns achieved a sensitivity of 94\% and a specificity of 94\% for detecting DLBCL samples in the test set of 85 samples, and achieved a sensitivity of 94\% and a specificity of 92\% for detecting poor prognosis patients in the test set of 66 samples. CONCLUSION: These proteomic patterns and potential biomarkers are hoped to be useful in clinical applications for detecting DLBCL patients and predicting the response to therapy.}, author = {Zhang, Xing and Wang, Bo and Zhang, Xiao-shi S. and Li, Zhi-ming M. and Guan, Zhong-zhen Z. and Jiang, Wen-qi Q.}, citeulike-article-id = {2180193}, citeulike-linkout-0 = {http://dx.doi.org/10.1186/1471-2407-7-235}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18163913}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18163913}, day = {29}, doi = {10.1186/1471-2407-7-235}, issn = {1471-2407}, journal = {BMC cancer}, keywords = {biomarker, cancer, lymphoma}, month = {December}, pages = {235+}, posted-at = {2009-04-27 17:49:32}, priority = {2}, title = {Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning.}, url = {http://dx.doi.org/10.1186/1471-2407-7-235}, volume = {7}, year = {2007} }

TY - JOUR ID - citeulike:2180193 L3 - citeulike-article-id:2180193 N2 - BACKGROUND: Currently, there are no satisfactory biomarkers available to screen for diffuse large B cell lymphoma (DLBCL) or to identify patients who do not benefit from standard anti-cancer therapies. In this study, we used serum proteomic mass spectra to identify potential serum biomarkers and biomarker patterns for detecting DLBCL and patient responses to therapy. METHODS: The proteomic spectra of crude sera from 132 patients with DLBCL and 75 controls were performed by SELDI-TOF-MS and analyzed by Biomarker Patterns Software. RESULTS: Nine peaks were considered as potential DLBCL discriminatory biomarkers. Four peaks were considered as biomarkers for predicting the patient response to standard therapy. The proteomic patterns achieved a sensitivity of 94% and a specificity of 94% for detecting DLBCL samples in the test set of 85 samples, and achieved a sensitivity of 94% and a specificity of 92% for detecting poor prognosis patients in the test set of 66 samples. CONCLUSION: These proteomic patterns and potential biomarkers are hoped to be useful in clinical applications for detecting DLBCL patients and predicting the response to therapy. JF - BMC cancer SN - 1471-2407 TI - Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning. VL - 7 SP - 235 KW - biomarker KW - cancer KW - lymphoma AU - Zhang, Xing AU - Wang, Bo AU - Zhang, Xiao-shi AU - Li, Zhi-ming AU - Guan, Zhong-zhen AU - Jiang, Wen-qi PY - 2007/12/29/ UR - http://dx.doi.org/10.1186/1471-2407-7-235 ER -